- Prev close
- $219.07
- Day range
- $219.00 – $226.43
- Next earnings
- in 36 days
BIIB’s 2026-09-15 move was a mild -0.5% decline alongside a -0.5% S&P 500 and a -0.7% Nasdaq 100, while recent company updates center on pipeline expansion and a series of late-stage readouts. The picture is mixed but not deteriorating, with solid margins and a rich valuation on backward earnings.
BIIB
BIOGEN INC
As of Sep 16, 2026
61/100
Worth keeping an eye onHealth ScoreWhy it moved
BIIB moved -0.5% on 2026-09-15, exactly in line with the S&P 500 at -0.5% and milder than the Nasdaq 100 at -0.7%, so the broad tape does explain the session at the index level. But the sector peer set was weaker, with REGN at -2.5% and MRNA at -2.0% while NTRA rose +2.6%, which makes BIIB’s move look more like ordinary market tracking than a sector-wide selloff. The main read is market-wide, not stock-specific: there was no company-specific negative catalyst in the facts, and the session was a small drift lower rather than a sharp re-rating.
Normal volatility?
This looks like ordinary volatility rather than a fundamentals break. Revenue is +0.3% YoY (TTM) and +3.4% YoY in the latest quarter, gross margin is +74.0%, operating margin is +10.9%, and net margin is +8.3%, so the business still has real profitability even though EPS is -46.0% YoY (TTM). Valuation is split: PE is 38.2 on trailing earnings, forward PE is 14.0, and PEG is 10.99, but that PEG is not meaningful here because EPS growth is negative, so the forward multiple matters more than the growth-adjusted one. Beta is 0.12, which also points to low day-to-day sensitivity; against that backdrop, a -0.5% move is not unusual and does not by itself signal deterioration. Analyst recommendation distribution is also constructive at 10 strong-positive, 20 positive, 12 neutral, 1 negative, and 0 strong-negative, which does not point to a consensus downgrade cycle.
Earnings preview
The next earnings date is 2026-10-28. The facts do not provide consensus revenue or EPS growth for that report, so I cannot quote market expectations for that specific print; the available fundamentals instead show revenue +0.3% YoY (TTM), latest-quarter revenue +3.4% YoY, and EPS -46.0% YoY (TTM). There is also no prior post-earnings reaction history in the facts, so I cannot characterize how the shares have tended to trade around prints. The market will likely focus on three concrete items already flagged in the recent company updates: whether the broader push beyond neuroscience is translating into durable pipeline breadth, whether the upcoming wave of Phase III readouts begins to de-risk the story, and whether expense control can support the stated goal of returning to growth.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track BIIB with WhyIHold
Get a plain-English explanation the next time BIOGEN INC makes a big move — so you know whether it's benign or worth your attention.